Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07296276 · ClinicalTrials.gov registry record · NA
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
A NA study of Type 1 Diabetes Mellitus, sponsored by i-SENS.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT07296276: Recruiting NA study of Type 1 Diabetes Mellitus, sponsored by i-SENS.
NCT07296276 is a NA study of Type 1 Diabetes Mellitus that is actively recruiting participants, run by i-SENS. The registered enrollment target is 32 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07296276, a NA study of Type 1 Diabetes Mellitus, is actively recruiting participants, sponsored by i-SENS.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, single arm, open-label, interventional, pilot study to evaluate the accuracy and precision of the continuous glucose monitoring (CGM) system of i-SENS, Inc., CareSens Air 3, in adult patients with type 1 diabetes.
Primary Outcome
percentage of iCGM values in the measuring range less than 70 mg/dL (3.9 mmol/l) within +/- 15 mg/dL (0.83 mmol/l) of the reference venous glucose measurement by YSI analyzer
Conditions Studied
Interventions
- DEVICE CareSens Air 3 primary insertion
- DEVICE CareSens Air 3 secondary insertion
Study Locations (4)
California
- Headlands Research AMCR - Escondido
- Diablo Clinical Research - Walnut Creek
Georgia
- Atlanta Diabetes Associates - Atlanta
Washington
- Rainier Clinical Reseach Center - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What NCT07296276 shows while recruiting
NCT07296276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which CareSens Air 3 primary insertion is the first listed.
NCT07296276 reports a single indexed study location in California, Georgia, Washington.
Frequently Asked Questions
What is clinical trial NCT07296276 about?
NCT07296276 is a clinical study titled "Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM". This is a prospective, single arm, open-label, interventional, pilot study to evaluate the accuracy and precision of the continuous glucose monitoring (CGM) system of i-SENS, Inc., CareSens Air 3, in adult patients with type 1 diabetes.
What is the current status of trial NCT07296276?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2026-02-09. Estimated completion is 2026-04-30.
What conditions does trial NCT07296276 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT07296276?
The interventions under investigation include: CareSens Air 3 primary insertion (DEVICE), CareSens Air 3 secondary insertion (DEVICE).
Who is sponsoring clinical trial NCT07296276?
This trial is sponsored by i-SENS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07296276 being conducted?
This trial has 4 study locations across California, Georgia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07296276's enrollment target sits among peer trials
32 68th of 112 higher than 42 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
-
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI